103RD GENERAL ASSEMBLY
State of Illinois
2023 and 2024
HB3721

 

Introduced 2/17/2023, by Rep. Terra Costa Howard

 

SYNOPSIS AS INTRODUCED:
 
New Act
720 ILCS 570/102  from Ch. 56 1/2, par. 1102

    Creates the Naturopathic Medical Practice Act. Provides for the licensure of naturopathic physicians. Creates the Naturopathic Physician Medical Board. Provides that the Board shall oversee the licensure of naturopathic physicians and matters relating to training and licensure of naturopathic physicians. Provides for membership of the Board and duties of the Board. Contains provisions concerning: definitions; qualifications for licensure; approval of naturopathic medical educational programs; display of license; scope of practice; referral requirements; prohibited conduct by licenses; exemptions from the Act; title protection; license expiration, renewal, denial, revocation, and continuing education; grounds for disciplinary action; investigation, notice, hearing; record of proceedings; and confidentiality. Amends the Illinois Controlled Substances Act. Adds internal references to naturopathic physicians in the definitions of "practitioner", "prescriber", and "prescription". Effective immediately.


LRB103 30237 AMQ 56665 b

 

 

A BILL FOR

 

HB3721LRB103 30237 AMQ 56665 b

1    AN ACT concerning regulation.
 
2    Be it enacted by the People of the State of Illinois,
3represented in the General Assembly:
 
4    Section 1. Short title. This Act may be cited as the
5Naturopathic Medical Practice Act.
 
6    Section 5. Purpose and findings. The practice of
7naturopathic medicine in the State is declared to affect the
8public health, safety, and welfare and to be subject to
9regulation and control in the public interest. It is further
10declared to be a matter of public interest that naturopathic
11physicians and the practice of naturopathic medicine, as
12defined in this Act, merit the confidence of the public, that
13only qualified persons be authorized to practice naturopathic
14medicine in the State, and that no person shall practice
15naturopathic medicine without a valid existing license to do
16so.
17    The State is facing an unprecedented physician shortage in
18urban counties and an even higher shortage in rural counties.
19The COVID-19 pandemic increased that shortage exponentially.
20Naturopathic physicians with a proper scope of practice can
21help fill this void.
22    The General Assembly recognizes that naturopathic
23physicians comprise a distinct health care profession that

 

 

HB3721- 2 -LRB103 30237 AMQ 56665 b

1affects the public health, safety, and welfare and that
2licensure of naturopathic physicians will increase freedom of
3choice in health care and help address the physician shortage
4in the State. This Act shall be liberally construed to best
5carry out these subjects and purposes.
 
6    Section 10. Definitions. In this Act:
7    "Approved naturopathic medical educational program" means
8an educational program that the Board has approved as meeting
9the requirements of Section 20 of this Act that prepares
10naturopathic physicians for the practice of naturopathic
11medicine.
12    "Association" means an entity that is approved by the
13American Association of Naturopathic Physicians, which entity
14represents the interests of naturopathic physicians in this
15State.
16    "Board" means the Naturopathic Physician Medical Board
17established pursuant to Section 55 of this Act.
18    "Clinical laboratory procedure" means the use of
19venipuncture consistent with naturopathic medical practice,
20commonly used diagnostic modalities consistent with
21naturopathic practice, the recording of a patient's health
22history, physical examination, ordering and interpretation of
23radiographic diagnostics and other standard imaging and
24examination of body orifices, excluding endoscopy and
25colonoscopy. "Clinical laboratory procedure" includes the

 

 

HB3721- 3 -LRB103 30237 AMQ 56665 b

1practice of obtaining samples of human tissues, except
2surgical excision beyond surgical excision that is authorized
3as a minor office procedure.
4    "Drug" has the same meaning as set forth in Section 102 of
5the Illinois Controlled Substances Act.
6    "Homeopathic medicine" means a system of medicine based on
7the use of infinitesimal doses of substances capable of
8producing symptoms similar to those of the disease treated, as
9listed in the Homeopathic Pharmacopoeia of the United States.
10    "Hygiene" means the use of preventive techniques,
11including personal hygiene for asepsis, public health, and
12safety.
13    "Laboratory examination" means:
14        (1) phlebotomy;
15        (2) a clinical laboratory procedure;
16        (3) an orificial examination;
17        (4) a physiological function test; and
18        (5) a screening or test that is consistent with
19    naturopathic education and training.
20    "Legend drug" has the same meaning as set forth in Section
213.23 of the Illinois Food, Drug and Cosmetic Act.
22    "License" means a license issued by the Board to an
23individual pursuant to this Act and rules authorizing that
24individual to practice naturopathic medicine in this State.
25    "Licensee" means a naturopathic physician licensed by the
26Board to practice naturopathic medicine in this State.

 

 

HB3721- 4 -LRB103 30237 AMQ 56665 b

1    "Minor office procedure" means minor surgical care and
2procedures, including:
3        (1) surgical care incidental to superficial
4    laceration, lesion, or abrasion, excluding surgical care
5    to treat a lesion suspected of malignancy;
6        (2) the removal of foreign bodies located in
7    superficial structures, excluding the globe of the eye;
8        (3) trigger point therapy;
9        (4) dermal stimulation;
10        (5) allergy testing and treatment; and
11        (6) the use of antiseptics and topical or local
12    anesthetics.
13    "Naturopathic medicine" means:
14        (1) a system of health care for the prevention,
15    diagnosis and treatment of human health conditions,
16    injury, and disease;
17        (2) the promotion or restoration of health; and
18        (3) the support and stimulation of a patient's
19    inherent self-healing processes through patient education
20    and the use of naturopathic therapies and therapeutic
21    substances.
22    "Naturopathic physical medicine" means the use of one or
23more of the following physical agents in a manner consistent
24with naturopathic medical practice on a part or the whole of
25the body, by hand or by mechanical means, in the resolution of
26a human ailment or conditions:

 

 

HB3721- 5 -LRB103 30237 AMQ 56665 b

1        (1) air;
2        (2) water;
3        (3) heat;
4        (4) cold;
5        (5) sound;
6        (6) light;
7        (7) electromagnetism;
8        (8) colon hydrotherapy;
9        (9) soft tissue therapy;
10        (10) joint mobilization;
11        (11) therapeutic exercise; or
12        (12) naturopathic manipulation.
13    "Naturopathic physician" means an individual licensed
14pursuant to this Act as a naturopathic physician to practice
15naturopathic medicine in this State.
16    "Naturopathic therapy" means the use of:
17        (1) naturopathic physical medicine;
18        (2) suggestion;
19        (3) hygiene;
20        (4) a therapeutic substance;
21        (5) nutrition and food science;
22        (6) homeopathic medicine;
23        (7) a clinical laboratory procedure; or
24        (8) a minor office procedure.
25    "Nutrition and food science" means the prevention and
26treatment of disease or other human conditions through the use

 

 

HB3721- 6 -LRB103 30237 AMQ 56665 b

1of food, water, herbs, roots, bark, or natural food elements.
2    "Prescription" has the same meaning as set forth in
3Section 3 of the Pharmacy Practice Act.
4    "Professional examination" means a competency based
5naturopathic physician licensing examination as determined by
6Department rule.
7    "Suggestion" means a technique using:
8        (1) biofeedback;
9        (2) hypnosis;
10        (3) health education; or
11        (4) health counseling.
12    "Telehealth" or "telepractice" means the delivery of
13services under this Act by using electronic communication,
14information technologies, or other means between an individual
15licensed under this Act in one location and a patient or client
16in another location, with or without an intervening healthcare
17provider. "Telehealth" or "telepractice" includes direct,
18interactive patient encounters, asynchronous
19store-and-forward technologies, and remote monitoring.
20Telehealth or telepractice is not prohibited under this Act
21provided that the provision of telehealth or telepractice
22services is appropriate for the client and the level of care
23provided meets the required level of care for that client.
24Individuals providing services regulated by this Act via
25telepractice shall comply with and are subject to all
26licensing and disciplinary provisions of this Act.

 

 

HB3721- 7 -LRB103 30237 AMQ 56665 b

1    "Therapeutic substance" means any of the following
2exemplified in a standard naturopathic medical text, journal,
3or pharmacopeia:
4        (1) a vitamin;
5        (2) a mineral;
6        (3) a nutraceutical;
7        (4) a botanical medicine;
8        (5) oxygen;
9        (6) a homeopathic medicine;
10        (7) a hormone;
11        (8) a hormonal or pharmaceutical contraceptive device;
12    or
13        (9) other physiologic substance.
 
14    Section 15. Qualifications for licensure. The Board shall
15license an applicant who:
16        (1) submits, in accordance with rules of the
17    Department, the following items to the Board:
18            (A) an application for licensure designed and
19        approved by the Board and submitted in accordance with
20        rules of the Department;
21            (B) an application fee submitted in an amount and
22        manner established by rules of the Department;
23            (C) evidence that the applicant has graduated from
24        a Council on Naturopathic Medical Education or an
25        equivalent federally recognized accrediting body,

 

 

HB3721- 8 -LRB103 30237 AMQ 56665 b

1        approved naturopathic medical education program;
2            (D) evidence that the applicant has passed a
3        professional examination authorized by rule of the
4        Department and administered by the North American
5        Board of Naturopathic Examiners or its successor;
6            (E) evidence that the applicant has passed a
7        pharmacy examination authorized by rules of the
8        Department and administered by the North American
9        Board of Naturopathic Examiners or its successor;
10            (F) evidence that the applicant has passed a minor
11        surgery examination authorized by rules of the
12        Department and administered by the North American
13        Board of Naturopathic Examiners or its successor; and
14            (G) evidence of professional liability insurance
15        with policy limits not less than prescribed by the
16        Department;
17        (2) is determined by the Board to be physically and
18    mentally capable of safely practicing naturopathic
19    medicine with or without reasonable accommodation; and
20        (3) has not had a license to practice naturopathic
21    medicine or other health care license, registration, or
22    certificate refused, revoked, or suspended by any other
23    jurisdiction for reasons that relate to the applicant's
24    ability to skillfully and safely practice naturopathic
25    medicine unless that license, registration, or
26    certification has been restored to good standing by that

 

 

HB3721- 9 -LRB103 30237 AMQ 56665 b

1    jurisdiction.
 
2    Section 20. Approved naturopathic medical educational
3program. The Department shall establish, by rule, guidelines
4for an approved naturopathic medical educational program,
5which guidelines shall meet the following requirements and the
6Department's specifications for the education of naturopathic
7physicians. The approved naturopathic medical educational
8program shall:
9        (1) offer graduate-level, full-time didactic and
10    supervised clinical training;
11        (2) be accredited, or have achieved candidacy status
12    for accreditation, by the Council on Naturopathic Medical
13    Education or an equivalent federally recognized
14    accrediting body for naturopathic medical programs that is
15    also recognized by the Department; and
16        (3) be conducted by an institution of higher
17    education, or a division of an institution of higher
18    education, that:
19            (A) is accredited or is a candidate for
20        accreditation by a regional or national institutional
21        accrediting agency recognized by the United States
22        Secretary of Education or a diploma-granting,
23        degree-equivalent college or university; or
24            (B) meets equivalent standards for recognition of
25        accreditation established by rules of the Department

 

 

HB3721- 10 -LRB103 30237 AMQ 56665 b

1        for medical education programs offered in Canada.
 
2    Section 25. Display of license. A licensee shall display
3the licensee's license in the licensee's place of business in
4a location clearly visible to the licensee's patients and
5shall also display evidence of the licensee having completed
6an approved naturopathic medical educational program.
 
7    Section 30. Scope of practice.
8    (a) A licensee may practice naturopathic medicine to
9provide primary care in alignment with naturopathic medical
10education to:
11        (1) perform physical examinations;
12        (2) order laboratory examinations;
13        (3) order diagnostic imaging studies;
14        (4) interpret the results of laboratory examinations
15    for diagnostic purposes;
16        (5) order and, based on a radiologist's report, take
17    action on diagnostic imaging studies in a manner
18    consistent with naturopathic training;
19        (6) prescribe, administer, dispense, and order food,
20    extracts of food, nutraceuticals, vitamins, amino acids,
21    minerals, enzymes, botanicals and their extracts,
22    botanical medicines, homeopathic medicines, dietary
23    supplements, and nonprescription drugs as defined by the
24    Federal Food, Drug, and Cosmetic Act;

 

 

HB3721- 11 -LRB103 30237 AMQ 56665 b

1        (7) dispense and order all legend drugs in the regular
2    course of practicing naturopathic medicine. The dispensing
3    of such legend drugs shall be the personal act of the
4    person licensed under this Act and may not be delegated to
5    any other person not licensed under this Act or the
6    Pharmacy Practice Act unless such delegated dispensing
7    functions are under the direct supervision of the
8    physician authorized to dispense legend drugs. Except when
9    dispensing manufacturers' samples or other legend drugs in
10    a maximum 72 hour supply, persons licensed under this Act
11    shall maintain a book or file of prescriptions as required
12    in the Pharmacy Practice Act. Any person licensed under
13    this Act who dispenses any drug or medicine shall dispense
14    such drug or medicine in good faith and shall affix to the
15    box, bottle, vessel or package containing the same a label
16    indicating (i) the date on which such drug or medicine is
17    dispensed; (ii) the name of the patient; (iii) the last
18    name of the person dispensing such drug or medicine; (iv)
19    the directions for use thereof; and (v) the proprietary
20    name or names or, if there are none, the established name
21    or names of the drug or medicine, the dosage and quantity,
22    except as otherwise authorized by regulation of the
23    Department;
24        (8) prescribe, administer, dispense, and order all
25    drugs within Schedules II-V of the Controlled Substances
26    Act;

 

 

HB3721- 12 -LRB103 30237 AMQ 56665 b

1        (9) use routes of administration that include oral,
2    nasal, auricular, ocular, rectal, vaginal, transdermal,
3    intradermal, subcutaneous, intravenous, intra-articular,
4    and intramuscular consistent with the education and
5    training of a naturopathic physician;
6        (10) administer intramuscular, intravenous,
7    subcutaneous, intra-articular and intradermal injections
8    of vaccines;
9        (11) administer intramuscular, intravenous,
10    subcutaneous, intra-articular and intradermal injections
11    of substances appropriate to naturopathic medicine;
12        (12) perform naturopathic physical medicine;
13        (13) employ the use of naturopathic therapy;
14        (14) use therapeutic devices, barrier contraception,
15    intrauterine devices, hormonal and pharmaceutical
16    contraception, and durable medical equipment; or
17        (15) perform minor office procedures.
18    (b) A licensee may practice naturopathic medicine via
19telehealth services.
 
20    Section 35. Referral requirement. A licensee shall refer
21to a physician licensed to practice medicine in all of its
22branches under the Medical Practice Act of 1987 or an advanced
23practice registered nurse licensed under the Nurse Practice
24Act any patient whose medical condition is determined, at the
25time of evaluation or treatment, to be beyond the scope of

 

 

HB3721- 13 -LRB103 30237 AMQ 56665 b

1practice of the licensee.
 
2    Section 40. Prohibitions. A licensee shall not:
3        (1) perform surgery outside of the scope of minor
4    office procedures permitted in the employment of
5    naturopathic therapy;
6        (2) use general or spinal anesthetics;
7        (3) administer ionizing radioactive substances for
8    therapeutic purposes;
9        (4) perform a surgical procedure using a laser device;
10        (5) perform a surgical procedure involving any of the
11    following areas of the body that extend beyond superficial
12    tissue:
13            (A) eyes;
14            (B) ears;
15            (C) tendons;
16            (D) nerves;
17            (E) veins; or
18            (F) arteries;
19        (6) perform a surgical abortion;
20        (7) treat any lesion suspected of malignancy or
21    requiring surgical removal; or
22        (8) perform acupuncture.
 
23    Section 45. Exemptions. Nothing in this Act shall be
24construed to prohibit or to restrict:

 

 

HB3721- 14 -LRB103 30237 AMQ 56665 b

1        (1) the practice of a health care profession by an
2    individual who is licensed, certified, or registered under
3    other laws of this State and who is performing services
4    within the individual's authorized scope of practice;
5        (2) the practice of naturopathic medicine by a student
6    enrolled in an approved naturopathic medical educational
7    program if the practice of naturopathic medicine by a
8    student is performed pursuant to a course of instruction
9    or an assignment from an instructor at an accredited
10    university or college by an instructor duly licensed as a
11    health care provider in the State;
12        (3) any person who sells a vitamin or herb from
13    providing information about the vitamin or herb;
14        (4) the practice of naturopathic medicine by persons
15    who are licensed to practice in any other state or
16    district in the United States and who enter this State to
17    consult with a naturopathic physician of this State if the
18    consultation is limited to an examination or
19    recommendation; or
20        (5) any person or practitioner who is not licensed as
21    a naturopathic physician from recommending ayurvedic
22    medicine, herbal remedies, nutritional advice, homeopathy,
23    or other therapy that is within the scope of practice of
24    naturopathic medicine; however, the person or practitioner
25    shall not:
26            (A) use a title protected pursuant to Section 50

 

 

HB3721- 15 -LRB103 30237 AMQ 56665 b

1        of this Act;
2            (B) represent or assume the character or
3        appearance of a licensee; or
4            (C) otherwise use a name, title, or other
5        designation that indicates or implies that the person
6        is a licensee.
 
7    Section 50. Protected titles.
8    (a) A licensee shall use the title "naturopathic
9physician", "naturopathic doctor", or "naturopathic medical
10doctor" and the recognized abbreviations "N.D." and "N.M.D.".
11    (b) A licensee has the exclusive right to use the
12following terms in reference to the licensee's self:
13        (1) "naturopathic physician";
14        (2) "naturopathic doctor";
15        (3) "naturopathic medical doctor";
16        (4) "doctor of naturopathic medicine";
17        (5) "doctor of naturopathy";
18        (6) "naturopath";
19        (7) "N.D.";
20        (8) "ND";
21        (9) "NMD"; and
22        (10) "N.M.D.".
23    (c) An individual represents the individual's self to be a
24naturopathic physician or a naturopathic doctor when the
25individual uses or adopts any of the following terms in

 

 

HB3721- 16 -LRB103 30237 AMQ 56665 b

1reference to the individual's self:
2        (1) "naturopathic physician";
3        (2) "naturopathic doctor";
4        (3) "naturopathic medical doctor";
5        (4) "doctor of naturopathic medicine";
6        (5) "doctor of naturopathy";
7        (6) "naturopath";
8        (7) "N.D.";
9        (8) "ND";
10        (9) "NMD"; and
11        (10) "N.M.D.".
12    (d) An individual shall not represent the individual's
13self to the public as a naturopathic physician, naturopathic
14doctor, naturopathic medical doctor, a doctor of naturopathic
15medicine, a doctor of naturopathy, or as being otherwise
16authorized to practice naturopathic medicine in this State,
17unless the individual is a licensee.
 
18    Section 55. Naturopathic Physician Medical Board.
19    (a) The Naturopathic Physician Medical Board shall
20oversee:
21        (1) licensure of naturopathic physicians; and
22        (2) matters relating to training and licensure of
23    naturopathic physicians.
24    (b) Within 180 days after the effective date of this Act,
25the Governor shall appoint an initial Board consisting of 2

 

 

HB3721- 17 -LRB103 30237 AMQ 56665 b

1members for terms of 4 years each, 3 members for terms of 3
2years each, and 4 members for terms of 2 years each. The
3initial Board shall consist of the following voting members:
4        (1) five licensed naturopathic physicians who are
5    residents of the State;
6        (2) two practicing physicians licensed to practice
7    medicine in all of its branches; and
8        (3) two public members who are residents of this
9    State, who are not, and never have been, a licensed health
10    care practitioner, and who do not have an interest in
11    naturopathic education, naturopathic medicine, or
12    naturopathic business or practice.
13    Members of the Board may be recommended to the Governor by
14the Illinois Association of Naturopathic Physicians.
15    (c) As the terms of the initial Board members expire, the
16Governor shall appoint successors for terms of 4 years each as
17follows:
18        (1) five naturopathic physicians licensed pursuant to
19    this Act;
20        (2) two practicing physicians licensed to practice
21    medicine in all of its branches with experience working
22    with naturopathic physicians; and
23        (3) two public members that are residents of this
24    State who are not, and never have been, a licensed health
25    care practitioner and who do not have an interest in
26    naturopathic education, naturopathic medicine or

 

 

HB3721- 18 -LRB103 30237 AMQ 56665 b

1    naturopathic business or practice.
2    (d) Within 30 days after the Board is established, the
3Board shall call the first meeting, at which meeting members
4shall elect a chair. The Board may hold meetings at the call of
5the chair or at the written request of any 2 members of the
6Board.
7    (e) Vacancies on the Board shall be filled from a list of
8not fewer than 3 candidates.
9    (f) A majority of the Board shall constitute a quorum.
10    (g) Members of the Board shall serve without compensation
11but may, at the discretion of the Board, be reimbursed for
12their expenses incurred in performing their duties.
13    (h) The Department of Financial and Professional
14Regulation shall provide administrative and other support to
15the Board.
 
16    Section 60. Board duties. The Board shall have the
17following duties:
18        (1) regulating the licensure of naturopathic
19    physicians and determining the hours of continuing
20    education units required for maintaining licensure as a
21    naturopathic physician;
22        (2) prescribing the manner in which records of
23    examinations and treatments shall be kept and maintained;
24        (3) establishing standards for professional
25    responsibility and conduct;

 

 

HB3721- 19 -LRB103 30237 AMQ 56665 b

1        (4) identifying disciplinary actions and circumstances
2    that require disciplinary action;
3        (5) developing a means to provide information to all
4    licensees in this State;
5        (6) providing for the investigation of complaints
6    against licensees or persons holding themselves out as
7    naturopathic physicians in this State;
8        (7) providing for the publication of information for
9    the public about licensees and the practice of
10    naturopathic medicine in this State;
11        (8) providing for an orderly process for reinstatement
12    of a license;
13        (9) establishing criteria for advertising or
14    promotional materials;
15        (10) establishing continuing education hours and
16    content;
17        (11) establishing procedures and standards for
18    reviewing licensing examination scores; and
19        (12) establishing procedures for reviewing transcripts
20    demonstrating completion of the approved naturopathic
21    medical educational program;
22        (13) establishing and maintaining a list of
23    naturopathic medical education programs that meet the
24    requirements of Section 20;
25        (14) establishing the requirements for issuance and
26    renewal of licenses; and

 

 

HB3721- 20 -LRB103 30237 AMQ 56665 b

1        (15) any other matter necessary to implement this Act.
 
2    Section 65. License expiration, renewal, denial,
3revocation, and continuing education.
4    (a) A license issued or renewed pursuant to this Act shall
5expire in a time frame determined by rule by the Department.
6    (b) The Board may renew the license of any licensee who,
7upon the expiration of the licensee's license:
8        (1) has submitted an application for renewal;
9        (2) has paid the renewal fee established by rules of
10    the Department;
11        (3) meets the qualifications for licensure set forth
12    in this Act and rules of the Department; and
13        (4) meets the continuing education requirements
14    established by the Board.
15    (c) If the Board intends to refuse to issue or renew,
16revoke, or suspend a license, the Department shall grant the
17applicant or licensee an opportunity for a hearing.
 
18    Section 70. Grounds for disciplinary action.
19    (a) The Department may refuse to issue or to renew, or may
20revoke, suspend, place on probation, reprimand, or take other
21disciplinary or non-disciplinary action with regard to any
22license issued under this Act as the Department may deem
23proper, including the issuance of fines not to exceed $10,000
24for each violation, for any one or combination of the

 

 

HB3721- 21 -LRB103 30237 AMQ 56665 b

1following causes:
2        (1) material misstatement in furnishing information to
3    the Department;
4        (2) violations of this Act, or the rules adopted under
5    this Act;
6        (3) conviction by plea of guilty or nolo contendere,
7    finding of guilt, jury verdict, or entry of judgment or
8    sentencing, including, but not limited to, convictions,
9    preceding sentences of supervision, conditional discharge,
10    or first offender probation, under the laws of any
11    jurisdiction of the United States that is: (i) a felony;
12    or (ii) a misdemeanor, an essential element of which is
13    dishonesty, or that is directly related to the practice of
14    the profession;
15        (4) making any misrepresentation for the purpose of
16    obtaining licenses;
17        (5) professional incompetence;
18        (6) aiding or assisting another person in violating
19    any provision of this Act or its rules;
20        (7) failing, within 60 days, to provide information in
21    response to a written request made by the Department;
22        (8) engaging in dishonorable, unethical, or
23    unprofessional conduct, as defined by rule, of a character
24    likely to deceive, defraud, or harm the public.
25        (9) habitual or excessive use or addiction to alcohol,
26    narcotics, stimulants, or any other chemical agent or drug

 

 

HB3721- 22 -LRB103 30237 AMQ 56665 b

1    that results in a naturopathic physician's inability to
2    practice with reasonable judgment, skill, or safety;
3        (10) discipline by another U.S. jurisdiction or
4    foreign nation, if at least one of the grounds for
5    discipline is the same or substantially equivalent to
6    those set forth in this Section;
7        (11) directly or indirectly giving to or receiving
8    from any person, firm, corporation, partnership, or
9    association any fee, commission, rebate or other form of
10    compensation for any professional services not actually or
11    personally rendered. Nothing in this paragraph (11)
12    affects any bona fide independent contractor or employment
13    arrangements, which may include provisions for
14    compensation, health insurance, pension, or other
15    employment benefits, with persons or entities authorized
16    under this Act for the provision of services within the
17    scope of the licensee's practice under this Act;
18        (12) abandonment of a patient;
19        (13) willfully making or filing false records or
20    reports in the individual's practice, including, but not
21    limited to, false records filed with state agencies or
22    departments;
23        (14) physical illness, or mental illness or impairment
24    that results in the inability to practice the profession
25    with reasonable judgment, skill, or safety, including, but
26    not limited to, deterioration through the aging process or

 

 

HB3721- 23 -LRB103 30237 AMQ 56665 b

1    loss of motor skill;
2        (15) being named as a perpetrator in an indicated
3    report by the Department of Children and Family Services
4    under the Abused and Neglected Child Reporting Act, and
5    upon proof by clear and convincing evidence that the
6    licensee has caused a child to be an abused child or
7    neglected child as defined in the Abused and Neglected
8    Child Reporting Act;
9        (16) gross negligence resulting in permanent injury or
10    death of a patient;
11        (17) employment of fraud, deception or any unlawful
12    means in applying for or securing a license under this
13    Act;
14        (18) immoral conduct in the commission of any act,
15    such as sexual abuse, sexual misconduct, or sexual
16    exploitation related to the licensee's practice;
17        (19) practicing under a false or assumed name, except
18    as provided by law;
19        (20) making a false or misleading statement regarding
20    the licensee's skill or the efficacy or value of the
21    treatment or remedy prescribed by the licensee in the
22    course of treatment;
23        (21) allowing another person to use the licensee's
24    license to practice;
25        (22) prescribing, selling, administering,
26    distributing, giving, or self-administering a drug

 

 

HB3721- 24 -LRB103 30237 AMQ 56665 b

1    classified as a controlled substance;
2        (23) a pattern of practice or other behavior that
3    demonstrates incapacity or incompetence to practice under
4    this Act;
5        (24) violating State or federal laws or regulations
6    relating to controlled substances or other legend drugs or
7    ephedra as defined in the Ephedra Prohibition Act;
8        (25) failure to establish and maintain records of
9    patient care and treatment as required by law;
10        (26) attempting to subvert or cheat on the required
11    examinations;
12        (27) willfully failing to report an instance of
13    suspected abuse, neglect, financial exploitation, or
14    self-neglect of an eligible adult as defined in and
15    required by the Adult Protective Services Act;
16        (28) being named as an abuser in a verified report by
17    the Department on Aging under the Adult Protective
18    Services Act and upon proof by clear and convincing
19    evidence that the licensee abused, neglected, or
20    financially exploited an eligible adult as defined in the
21    Adult Protective Services Act;
22        (29) failure to report to the Department an adverse
23    final action taken against the individual by another
24    licensing jurisdiction of the United States or a foreign
25    state or country, a peer review body, a health care
26    institution, a professional society or association, a

 

 

HB3721- 25 -LRB103 30237 AMQ 56665 b

1    governmental agency, a law enforcement agency, or a court
2    acts or conduct similar to acts or conduct that would
3    constitute grounds for action under this Section; and
4        (30) failure to provide copies of records of patient
5    care or treatment, except as required by law.
6    (b) The Department may refuse to issue or may suspend
7without hearing, as provided for in the Code of Civil
8Procedure, the license of any person who fails to file a
9return, or pay the tax, penalty, or interest shown in a filed
10return, or pay any final assessment of the tax, penalty, or
11interest as required by any tax Act administered by the
12Illinois Department of Revenue, until the requirements of any
13such tax Act are satisfied in accordance with subsection (g)
14of Section 2105-15 of the Civil Administrative Code of
15Illinois.
16    (c) The determination by a circuit court that a licensee
17is subject to involuntary admission or judicial admission as
18provided in the Mental Health and Developmental Disabilities
19Code operates as an automatic suspension. The suspension will
20end only upon a finding by a court that the patient is no
21longer subject to involuntary admission or judicial admission
22and issues an order so finding and discharging the patient,
23and upon the recommendation of the Board to the Department
24that the licensee be allowed to resume the licensee's
25practice.
26    (d) In enforcing this Section, the Department upon a

 

 

HB3721- 26 -LRB103 30237 AMQ 56665 b

1showing of a possible violation may compel an individual
2licensed to practice under this Act, or who has applied for
3licensure under this Act, to submit to a mental or physical
4examination, or both, which may include a substance abuse or
5sexual offender evaluation, as required by and at the expense
6of the Department.
7    The Department shall specifically designate the examining
8physician licensed to practice medicine in all of its branches
9or, if applicable, the multidisciplinary team involved in
10providing the mental or physical examination or both. The
11multidisciplinary team shall be led by a physician licensed to
12practice medicine in all of its branches and may consist of one
13or more or a combination of physicians licensed to practice
14medicine in all of its branches, licensed clinical
15psychologists, licensed clinical social workers, licensed
16clinical professional counselors, and other professional and
17administrative staff. Any examining physician or member of the
18multidisciplinary team may require any person ordered to
19submit to an examination pursuant to this Section to submit to
20any additional supplemental testing deemed necessary to
21complete any examination or evaluation process, including, but
22not limited to, blood testing, urinalysis, psychological
23testing, or neuropsychological testing.
24    The Department may order the examining physician or any
25member of the multidisciplinary team to provide to the
26Department any and all records, including business records,

 

 

HB3721- 27 -LRB103 30237 AMQ 56665 b

1that relate to the examination and evaluation, including any
2supplemental testing performed.
3    The Department may order the examining physician or any
4member of the multidisciplinary team to present testimony
5concerning the mental or physical examination of the licensee
6or applicant. No information, report, record, or other
7documents in any way related to the examination shall be
8excluded by reason of any common law or statutory privilege
9relating to communications between the licensee or applicant
10and the examining physician or any member of the
11multidisciplinary team. No authorization is necessary from the
12licensee or applicant ordered to undergo an examination for
13the examining physician or any member of the multidisciplinary
14team to provide information, reports, records, or other
15documents or to provide any testimony regarding the
16examination and evaluation.
17    The individual to be examined may have, at the
18individual's own expense, another physician of the
19individual's choice present during all aspects of this
20examination. However, that physician shall be present only to
21observe and may not interfere in any way with the examination.
22    Failure of an individual to submit to a mental or physical
23examination, when ordered, shall result in an automatic
24suspension of the individual's license until the individual
25submits to the examination.
26    If the Department finds an individual unable to practice

 

 

HB3721- 28 -LRB103 30237 AMQ 56665 b

1because of the reasons set forth in this Section, the
2Department may require that individual to submit to care,
3counseling, or treatment by physicians approved or designated
4by the Department, as a condition, term, or restriction for
5continued, reinstated, or renewed licensure to practice; or,
6in lieu of care, counseling, or treatment, the Department may
7file a complaint to immediately suspend, revoke, or otherwise
8discipline the license of the individual. An individual whose
9license was granted, continued, reinstated, renewed,
10disciplined, or supervised subject to such terms, conditions,
11or restrictions, and who fails to comply with such terms,
12conditions, or restrictions, shall be referred to the
13Secretary for a determination as to whether the individual
14shall have his or her license suspended immediately, pending a
15hearing by the Department.
16    In instances in which the Department immediately suspends
17a person's license under this Section, a hearing on that
18person's license must be convened by the Department within 30
19days after the suspension and completed without appreciable
20delay. The Department shall have the authority to review the
21subject individual's record of treatment and counseling
22regarding the impairment to the extent permitted by applicable
23federal statutes and regulations safeguarding the
24confidentiality of medical records.
25    An individual licensed under this Act and affected under
26this Section shall be afforded an opportunity to demonstrate

 

 

HB3721- 29 -LRB103 30237 AMQ 56665 b

1to the Department that the individual can resume practice in
2compliance with acceptable and prevailing standards under the
3provisions of the individual's license.
4    (e) An individual or organization acting in good faith,
5and not in a willful and wanton manner, in complying with this
6Section by providing a report or other information to the
7Department, by assisting in the investigation or preparation
8of a report or information, by participating in proceedings of
9the Department, or by serving as a member of the Department,
10shall not be subject to criminal prosecution or civil damages
11as a result of such actions.
12    (f) Members of the Board and the Department shall be
13indemnified by the State for any actions occurring within the
14scope of services under the Act, done in good faith and not
15willful and wanton in nature. The Attorney General shall
16defend all such actions unless the Attorney General determines
17either that there would be a conflict of interest in such
18representation or that the actions complained of were not in
19good faith or were willful and wanton.
20    If the Attorney General declines representation, the
21member has the right to employ counsel of the member's choice,
22whose fees shall be provided by the State, after approval by
23the Attorney General, unless there is a determination by a
24court that the member's actions were not in good faith or were
25willful and wanton.
26    The member must notify the Attorney General within 7 days

 

 

HB3721- 30 -LRB103 30237 AMQ 56665 b

1after receipt of notice of the initiation of any action
2involving services of the Board. Failure to so notify the
3Attorney General constitutes an absolute waiver of the right
4to a defense and indemnification.
5    The Attorney General shall determine, within 7 days after
6receiving such notice, whether the Attorney General will
7undertake to represent the member.
 
8    Section 75. Investigation; notice; hearing. The Department
9may investigate the actions of any applicant or of any person
10or persons holding or claiming to hold a license. The
11Department shall, before suspending, revoking, placing on
12probationary status, or taking any other disciplinary action
13as the Department may deem proper with regard to any license,
14at least 30 days prior to the date set for the hearing, notify
15the licensee in writing of any charges made and the time and
16place for a hearing of the charges before the Department,
17direct the licensee to file the licensee's written answer
18thereto to the Department under oath within 20 days after the
19service on the licensee of such notice and inform the licensee
20that if the licensee fails to file such answer, default will be
21taken against the licensee and the license may be suspended,
22revoked, placed on probationary status, or have other
23disciplinary action, including limiting the scope, nature or
24extent of the licensee's practice, as the Department may deem
25proper taken with regard thereto. Written or electronic notice

 

 

HB3721- 31 -LRB103 30237 AMQ 56665 b

1may be served by personal delivery, email, or mail to the
2applicant or licensee at the licensee's address of record or
3email address of record. At the time and place fixed in the
4notice, the Department shall proceed to hear the charges and
5the parties or their counsel shall be accorded ample
6opportunity to present such statements, testimony, evidence,
7and argument as may be pertinent to the charges or to the
8defense thereto. The Department may continue such hearing from
9time to time. In case the applicant or licensee, after
10receiving notice, fails to file an answer, the licensee's
11license may in the discretion of the Secretary, having
12received first the recommendation of the Department, be
13suspended, revoked, placed on probationary status, or the
14Department may take whatever disciplinary action as the
15Department may deem proper, including limiting the scope,
16nature, or extent of such person's practice, without a
17hearing, if the act or acts charged constitute sufficient
18grounds for such action under this Act.
 
19    Section 80. Record of proceedings. The Department, at its
20expense, shall preserve a record of all proceedings at the
21formal hearing of any case involving the refusal to issue or
22renew a license or discipline a licensee. The notice of
23hearing, complaint, and all other documents in the nature of
24pleadings and written motions filed in the proceedings, the
25transcript of testimony, the report of the Department, and

 

 

HB3721- 32 -LRB103 30237 AMQ 56665 b

1orders of the Department shall be the record of such
2proceeding.
 
3    Section 85. Confidentiality. All information collected by
4the Department in the course of an examination or
5investigation of a licensee or applicant, including, but not
6limited to, any complaint against a licensee filed with the
7Department and information collected to investigate any such
8complaint, shall be maintained for the confidential use of the
9Department and shall not be disclosed. The Department shall
10not disclose the information to anyone other than law
11enforcement officials, regulatory agencies that have an
12appropriate regulatory interest as determined by the
13Department, or a party presenting a lawful subpoena to the
14Department. Information and documents disclosed to a federal,
15State, county, or local law enforcement agency shall not be
16disclosed by the agency for any purpose to any other agency or
17person. A formal complaint filed against a licensee by the
18Department or any order issued by the Department against a
19licensee or applicant shall be a public record, except as
20otherwise prohibited by law.
 
21    Section 90. Illinois Administrative Procedure Act. The
22Illinois Administrative Procedure Act is expressly adopted and
23incorporated herein as if all of the provisions of that Act
24were included in this Act, except that the provision of

 

 

HB3721- 33 -LRB103 30237 AMQ 56665 b

1paragraph (d) of Section 10-65 of the Illinois Administrative
2Procedure Act, which provides that at hearings the licensee or
3person holding a license has the right to show compliance with
4all lawful requirements for retention or continuation of the
5license, is specifically excluded. For the purpose of this
6Act, the notice required under Section 10-25 of the Illinois
7Administrative Procedure Act is deemed sufficient when
8personally served, mailed to the address of record of the
9applicant or licensee, or emailed to the email address of
10record of the applicant or licensee.
 
11    Section 100. The Illinois Controlled Substances Act is
12amended by changing Section 102 as follows:
 
13    (720 ILCS 570/102)  (from Ch. 56 1/2, par. 1102)
14    Sec. 102. Definitions. As used in this Act, unless the
15context otherwise requires:
16    (a) "Addict" means any person who habitually uses any
17drug, chemical, substance or dangerous drug other than alcohol
18so as to endanger the public morals, health, safety or welfare
19or who is so far addicted to the use of a dangerous drug or
20controlled substance other than alcohol as to have lost the
21power of self control with reference to his or her addiction.
22    (b) "Administer" means the direct application of a
23controlled substance, whether by injection, inhalation,
24ingestion, or any other means, to the body of a patient,

 

 

HB3721- 34 -LRB103 30237 AMQ 56665 b

1research subject, or animal (as defined by the Humane
2Euthanasia in Animal Shelters Act) by:
3        (1) a practitioner (or, in his or her presence, by his
4    or her authorized agent),
5        (2) the patient or research subject pursuant to an
6    order, or
7        (3) a euthanasia technician as defined by the Humane
8    Euthanasia in Animal Shelters Act.
9    (c) "Agent" means an authorized person who acts on behalf
10of or at the direction of a manufacturer, distributor,
11dispenser, prescriber, or practitioner. It does not include a
12common or contract carrier, public warehouseman or employee of
13the carrier or warehouseman.
14    (c-1) "Anabolic Steroids" means any drug or hormonal
15substance, chemically and pharmacologically related to
16testosterone (other than estrogens, progestins,
17corticosteroids, and dehydroepiandrosterone), and includes:
18    (i) 3[beta],17-dihydroxy-5a-androstane, 
19    (ii) 3[alpha],17[beta]-dihydroxy-5a-androstane, 
20    (iii) 5[alpha]-androstan-3,17-dione, 
21    (iv) 1-androstenediol (3[beta], 
22        17[beta]-dihydroxy-5[alpha]-androst-1-ene), 
23    (v) 1-androstenediol (3[alpha], 
24        17[beta]-dihydroxy-5[alpha]-androst-1-ene), 
25    (vi) 4-androstenediol  
26        (3[beta],17[beta]-dihydroxy-androst-4-ene), 

 

 

HB3721- 35 -LRB103 30237 AMQ 56665 b

1    (vii) 5-androstenediol  
2        (3[beta],17[beta]-dihydroxy-androst-5-ene), 
3    (viii) 1-androstenedione  
4        ([5alpha]-androst-1-en-3,17-dione), 
5    (ix) 4-androstenedione  
6        (androst-4-en-3,17-dione), 
7    (x) 5-androstenedione  
8        (androst-5-en-3,17-dione), 
9    (xi) bolasterone (7[alpha],17a-dimethyl-17[beta]- 
10        hydroxyandrost-4-en-3-one), 
11    (xii) boldenone (17[beta]-hydroxyandrost- 
12        1,4,-diene-3-one), 
13    (xiii) boldione (androsta-1,4- 
14        diene-3,17-dione), 
15    (xiv) calusterone (7[beta],17[alpha]-dimethyl-17 
16        [beta]-hydroxyandrost-4-en-3-one), 
17    (xv) clostebol (4-chloro-17[beta]- 
18        hydroxyandrost-4-en-3-one), 
19    (xvi) dehydrochloromethyltestosterone (4-chloro- 
20        17[beta]-hydroxy-17[alpha]-methyl- 
21        androst-1,4-dien-3-one), 
22    (xvii) desoxymethyltestosterone 
23    (17[alpha]-methyl-5[alpha] 
24        -androst-2-en-17[beta]-ol)(a.k.a., madol), 
25    (xviii) [delta]1-dihydrotestosterone (a.k.a.  
26        '1-testosterone') (17[beta]-hydroxy- 

 

 

HB3721- 36 -LRB103 30237 AMQ 56665 b

1        5[alpha]-androst-1-en-3-one), 
2    (xix) 4-dihydrotestosterone (17[beta]-hydroxy- 
3        androstan-3-one), 
4    (xx) drostanolone (17[beta]-hydroxy-2[alpha]-methyl- 
5        5[alpha]-androstan-3-one), 
6    (xxi) ethylestrenol (17[alpha]-ethyl-17[beta]- 
7        hydroxyestr-4-ene), 
8    (xxii) fluoxymesterone (9-fluoro-17[alpha]-methyl- 
9        1[beta],17[beta]-dihydroxyandrost-4-en-3-one), 
10    (xxiii) formebolone (2-formyl-17[alpha]-methyl-11[alpha], 
11        17[beta]-dihydroxyandrost-1,4-dien-3-one), 
12    (xxiv) furazabol (17[alpha]-methyl-17[beta]- 
13        hydroxyandrostano[2,3-c]-furazan), 
14    (xxv) 13[beta]-ethyl-17[beta]-hydroxygon-4-en-3-one, 
15    (xxvi) 4-hydroxytestosterone (4,17[beta]-dihydroxy- 
16        androst-4-en-3-one), 
17    (xxvii) 4-hydroxy-19-nortestosterone (4,17[beta]- 
18        dihydroxy-estr-4-en-3-one), 
19    (xxviii) mestanolone (17[alpha]-methyl-17[beta]- 
20        hydroxy-5-androstan-3-one), 
21    (xxix) mesterolone (1amethyl-17[beta]-hydroxy- 
22        [5a]-androstan-3-one), 
23    (xxx) methandienone (17[alpha]-methyl-17[beta]- 
24        hydroxyandrost-1,4-dien-3-one), 
25    (xxxi) methandriol (17[alpha]-methyl-3[beta],17[beta]- 
26        dihydroxyandrost-5-ene), 

 

 

HB3721- 37 -LRB103 30237 AMQ 56665 b

1    (xxxii) methenolone (1-methyl-17[beta]-hydroxy- 
2        5[alpha]-androst-1-en-3-one), 
3    (xxxiii) 17[alpha]-methyl-3[beta], 17[beta]- 
4        dihydroxy-5a-androstane, 
5    (xxxiv) 17[alpha]-methyl-3[alpha],17[beta]-dihydroxy 
6        -5a-androstane, 
7    (xxxv) 17[alpha]-methyl-3[beta],17[beta]- 
8        dihydroxyandrost-4-ene), 
9    (xxxvi) 17[alpha]-methyl-4-hydroxynandrolone (17[alpha]- 
10        methyl-4-hydroxy-17[beta]-hydroxyestr-4-en-3-one), 
11    (xxxvii) methyldienolone (17[alpha]-methyl-17[beta]- 
12        hydroxyestra-4,9(10)-dien-3-one), 
13    (xxxviii) methyltrienolone (17[alpha]-methyl-17[beta]- 
14        hydroxyestra-4,9-11-trien-3-one), 
15    (xxxix) methyltestosterone (17[alpha]-methyl-17[beta]- 
16        hydroxyandrost-4-en-3-one), 
17    (xl) mibolerone (7[alpha],17a-dimethyl-17[beta]- 
18        hydroxyestr-4-en-3-one), 
19    (xli) 17[alpha]-methyl-[delta]1-dihydrotestosterone  
20        (17b[beta]-hydroxy-17[alpha]-methyl-5[alpha]- 
21        androst-1-en-3-one)(a.k.a. '17-[alpha]-methyl- 
22        1-testosterone'), 
23    (xlii) nandrolone (17[beta]-hydroxyestr-4-en-3-one), 
24    (xliii) 19-nor-4-androstenediol (3[beta], 17[beta]- 
25        dihydroxyestr-4-ene), 
26    (xliv) 19-nor-4-androstenediol (3[alpha], 17[beta]- 

 

 

HB3721- 38 -LRB103 30237 AMQ 56665 b

1        dihydroxyestr-4-ene), 
2    (xlv) 19-nor-5-androstenediol (3[beta], 17[beta]- 
3        dihydroxyestr-5-ene), 
4    (xlvi) 19-nor-5-androstenediol (3[alpha], 17[beta]- 
5        dihydroxyestr-5-ene), 
6    (xlvii) 19-nor-4,9(10)-androstadienedione  
7        (estra-4,9(10)-diene-3,17-dione), 
8    (xlviii) 19-nor-4-androstenedione (estr-4- 
9        en-3,17-dione), 
10    (xlix) 19-nor-5-androstenedione (estr-5- 
11        en-3,17-dione), 
12    (l) norbolethone (13[beta], 17a-diethyl-17[beta]- 
13        hydroxygon-4-en-3-one), 
14    (li) norclostebol (4-chloro-17[beta]- 
15        hydroxyestr-4-en-3-one), 
16    (lii) norethandrolone (17[alpha]-ethyl-17[beta]- 
17        hydroxyestr-4-en-3-one), 
18    (liii) normethandrolone (17[alpha]-methyl-17[beta]- 
19        hydroxyestr-4-en-3-one), 
20    (liv) oxandrolone (17[alpha]-methyl-17[beta]-hydroxy- 
21        2-oxa-5[alpha]-androstan-3-one), 
22    (lv) oxymesterone (17[alpha]-methyl-4,17[beta]- 
23        dihydroxyandrost-4-en-3-one), 
24    (lvi) oxymetholone (17[alpha]-methyl-2-hydroxymethylene- 
25        17[beta]-hydroxy-(5[alpha]-androstan-3-one), 
26    (lvii) stanozolol (17[alpha]-methyl-17[beta]-hydroxy- 

 

 

HB3721- 39 -LRB103 30237 AMQ 56665 b

1        (5[alpha]-androst-2-eno[3,2-c]-pyrazole), 
2    (lviii) stenbolone (17[beta]-hydroxy-2-methyl- 
3        (5[alpha]-androst-1-en-3-one), 
4    (lix) testolactone (13-hydroxy-3-oxo-13,17- 
5        secoandrosta-1,4-dien-17-oic 
6        acid lactone), 
7    (lx) testosterone (17[beta]-hydroxyandrost- 
8        4-en-3-one), 
9    (lxi) tetrahydrogestrinone (13[beta], 17[alpha]- 
10        diethyl-17[beta]-hydroxygon- 
11        4,9,11-trien-3-one), 
12    (lxii) trenbolone (17[beta]-hydroxyestr-4,9, 
13        11-trien-3-one). 
14    Any person who is otherwise lawfully in possession of an
15anabolic steroid, or who otherwise lawfully manufactures,
16distributes, dispenses, delivers, or possesses with intent to
17deliver an anabolic steroid, which anabolic steroid is
18expressly intended for and lawfully allowed to be administered
19through implants to livestock or other nonhuman species, and
20which is approved by the Secretary of Health and Human
21Services for such administration, and which the person intends
22to administer or have administered through such implants,
23shall not be considered to be in unauthorized possession or to
24unlawfully manufacture, distribute, dispense, deliver, or
25possess with intent to deliver such anabolic steroid for
26purposes of this Act.

 

 

HB3721- 40 -LRB103 30237 AMQ 56665 b

1    (d) "Administration" means the Drug Enforcement
2Administration, United States Department of Justice, or its
3successor agency.
4    (d-5) "Clinical Director, Prescription Monitoring Program"
5means a Department of Human Services administrative employee
6licensed to either prescribe or dispense controlled substances
7who shall run the clinical aspects of the Department of Human
8Services Prescription Monitoring Program and its Prescription
9Information Library.
10    (d-10) "Compounding" means the preparation and mixing of
11components, excluding flavorings, (1) as the result of a
12prescriber's prescription drug order or initiative based on
13the prescriber-patient-pharmacist relationship in the course
14of professional practice or (2) for the purpose of, or
15incident to, research, teaching, or chemical analysis and not
16for sale or dispensing. "Compounding" includes the preparation
17of drugs or devices in anticipation of receiving prescription
18drug orders based on routine, regularly observed dispensing
19patterns. Commercially available products may be compounded
20for dispensing to individual patients only if both of the
21following conditions are met: (i) the commercial product is
22not reasonably available from normal distribution channels in
23a timely manner to meet the patient's needs and (ii) the
24prescribing practitioner has requested that the drug be
25compounded.
26    (e) "Control" means to add a drug or other substance, or

 

 

HB3721- 41 -LRB103 30237 AMQ 56665 b

1immediate precursor, to a Schedule whether by transfer from
2another Schedule or otherwise.
3    (f) "Controlled Substance" means (i) a drug, substance,
4immediate precursor, or synthetic drug in the Schedules of
5Article II of this Act or (ii) a drug or other substance, or
6immediate precursor, designated as a controlled substance by
7the Department through administrative rule. The term does not
8include distilled spirits, wine, malt beverages, or tobacco,
9as those terms are defined or used in the Liquor Control Act of
101934 and the Tobacco Products Tax Act of 1995.
11    (f-5) "Controlled substance analog" means a substance:
12        (1) the chemical structure of which is substantially
13    similar to the chemical structure of a controlled
14    substance in Schedule I or II;
15        (2) which has a stimulant, depressant, or
16    hallucinogenic effect on the central nervous system that
17    is substantially similar to or greater than the stimulant,
18    depressant, or hallucinogenic effect on the central
19    nervous system of a controlled substance in Schedule I or
20    II; or
21        (3) with respect to a particular person, which such
22    person represents or intends to have a stimulant,
23    depressant, or hallucinogenic effect on the central
24    nervous system that is substantially similar to or greater
25    than the stimulant, depressant, or hallucinogenic effect
26    on the central nervous system of a controlled substance in

 

 

HB3721- 42 -LRB103 30237 AMQ 56665 b

1    Schedule I or II.
2    (g) "Counterfeit substance" means a controlled substance,
3which, or the container or labeling of which, without
4authorization bears the trademark, trade name, or other
5identifying mark, imprint, number or device, or any likeness
6thereof, of a manufacturer, distributor, or dispenser other
7than the person who in fact manufactured, distributed, or
8dispensed the substance.
9    (h) "Deliver" or "delivery" means the actual, constructive
10or attempted transfer of possession of a controlled substance,
11with or without consideration, whether or not there is an
12agency relationship. "Deliver" or "delivery" does not include
13the donation of drugs to the extent permitted under the
14Illinois Drug Reuse Opportunity Program Act.
15    (i) "Department" means the Illinois Department of Human
16Services (as successor to the Department of Alcoholism and
17Substance Abuse) or its successor agency.
18    (j) (Blank).
19    (k) "Department of Corrections" means the Department of
20Corrections of the State of Illinois or its successor agency.
21    (l) "Department of Financial and Professional Regulation"
22means the Department of Financial and Professional Regulation
23of the State of Illinois or its successor agency.
24    (m) "Depressant" means any drug that (i) causes an overall
25depression of central nervous system functions, (ii) causes
26impaired consciousness and awareness, and (iii) can be

 

 

HB3721- 43 -LRB103 30237 AMQ 56665 b

1habit-forming or lead to a substance abuse problem, including,
2but not limited to, alcohol, cannabis and its active
3principles and their analogs, benzodiazepines and their
4analogs, barbiturates and their analogs, opioids (natural and
5synthetic) and their analogs, and chloral hydrate and similar
6sedative hypnotics.
7    (n) (Blank).
8    (o) "Director" means the Director of the Illinois State
9Police or his or her designated agents.
10    (p) "Dispense" means to deliver a controlled substance to
11an ultimate user or research subject by or pursuant to the
12lawful order of a prescriber, including the prescribing,
13administering, packaging, labeling, or compounding necessary
14to prepare the substance for that delivery.
15    (q) "Dispenser" means a practitioner who dispenses.
16    (r) "Distribute" means to deliver, other than by
17administering or dispensing, a controlled substance.
18    (s) "Distributor" means a person who distributes.
19    (t) "Drug" means (1) substances recognized as drugs in the
20official United States Pharmacopoeia, Official Homeopathic
21Pharmacopoeia of the United States, or official National
22Formulary, or any supplement to any of them; (2) substances
23intended for use in diagnosis, cure, mitigation, treatment, or
24prevention of disease in man or animals; (3) substances (other
25than food) intended to affect the structure of any function of
26the body of man or animals and (4) substances intended for use

 

 

HB3721- 44 -LRB103 30237 AMQ 56665 b

1as a component of any article specified in clause (1), (2), or
2(3) of this subsection. It does not include devices or their
3components, parts, or accessories.
4    (t-3) "Electronic health record" or "EHR" means an
5electronic record of health-related information on an
6individual that is created, gathered, managed, and consulted
7by authorized health care clinicians and staff.
8    (t-3.5) "Electronic health record system" or "EHR system"
9means any computer-based system or combination of federally
10certified Health IT Modules (defined at 42 CFR 170.102 or its
11successor) used as a repository for electronic health records
12and accessed or updated by a prescriber or authorized
13surrogate in the ordinary course of his or her medical
14practice. For purposes of connecting to the Prescription
15Information Library maintained by the Bureau of Pharmacy and
16Clinical Support Systems or its successor, an EHR system may
17connect to the Prescription Information Library directly or
18through all or part of a computer program or system that is a
19federally certified Health IT Module maintained by a third
20party and used by the EHR system to secure access to the
21database.
22    (t-4) "Emergency medical services personnel" has the
23meaning ascribed to it in the Emergency Medical Services (EMS)
24Systems Act.
25    (t-5) "Euthanasia agency" means an entity certified by the
26Department of Financial and Professional Regulation for the

 

 

HB3721- 45 -LRB103 30237 AMQ 56665 b

1purpose of animal euthanasia that holds an animal control
2facility license or animal shelter license under the Animal
3Welfare Act. A euthanasia agency is authorized to purchase,
4store, possess, and utilize Schedule II nonnarcotic and
5Schedule III nonnarcotic drugs for the sole purpose of animal
6euthanasia.
7    (t-10) "Euthanasia drugs" means Schedule II or Schedule
8III substances (nonnarcotic controlled substances) that are
9used by a euthanasia agency for the purpose of animal
10euthanasia.
11    (u) "Good faith" means the prescribing or dispensing of a
12controlled substance by a practitioner in the regular course
13of professional treatment to or for any person who is under his
14or her treatment for a pathology or condition other than that
15individual's physical or psychological dependence upon or
16addiction to a controlled substance, except as provided
17herein: and application of the term to a pharmacist shall mean
18the dispensing of a controlled substance pursuant to the
19prescriber's order which in the professional judgment of the
20pharmacist is lawful. The pharmacist shall be guided by
21accepted professional standards, including, but not limited
22to, the following, in making the judgment:
23        (1) lack of consistency of prescriber-patient
24    relationship,
25        (2) frequency of prescriptions for same drug by one
26    prescriber for large numbers of patients,

 

 

HB3721- 46 -LRB103 30237 AMQ 56665 b

1        (3) quantities beyond those normally prescribed,
2        (4) unusual dosages (recognizing that there may be
3    clinical circumstances where more or less than the usual
4    dose may be used legitimately),
5        (5) unusual geographic distances between patient,
6    pharmacist and prescriber,
7        (6) consistent prescribing of habit-forming drugs.
8    (u-0.5) "Hallucinogen" means a drug that causes markedly
9altered sensory perception leading to hallucinations of any
10type.
11    (u-1) "Home infusion services" means services provided by
12a pharmacy in compounding solutions for direct administration
13to a patient in a private residence, long-term care facility,
14or hospice setting by means of parenteral, intravenous,
15intramuscular, subcutaneous, or intraspinal infusion.
16    (u-5) "Illinois State Police" means the Illinois State
17Police or its successor agency.
18    (v) "Immediate precursor" means a substance:
19        (1) which the Department has found to be and by rule
20    designated as being a principal compound used, or produced
21    primarily for use, in the manufacture of a controlled
22    substance;
23        (2) which is an immediate chemical intermediary used
24    or likely to be used in the manufacture of such controlled
25    substance; and
26        (3) the control of which is necessary to prevent,

 

 

HB3721- 47 -LRB103 30237 AMQ 56665 b

1    curtail or limit the manufacture of such controlled
2    substance.
3    (w) "Instructional activities" means the acts of teaching,
4educating or instructing by practitioners using controlled
5substances within educational facilities approved by the State
6Board of Education or its successor agency.
7    (x) "Local authorities" means a duly organized State,
8County or Municipal peace unit or police force.
9    (y) "Look-alike substance" means a substance, other than a
10controlled substance which (1) by overall dosage unit
11appearance, including shape, color, size, markings or lack
12thereof, taste, consistency, or any other identifying physical
13characteristic of the substance, would lead a reasonable
14person to believe that the substance is a controlled
15substance, or (2) is expressly or impliedly represented to be
16a controlled substance or is distributed under circumstances
17which would lead a reasonable person to believe that the
18substance is a controlled substance. For the purpose of
19determining whether the representations made or the
20circumstances of the distribution would lead a reasonable
21person to believe the substance to be a controlled substance
22under this clause (2) of subsection (y), the court or other
23authority may consider the following factors in addition to
24any other factor that may be relevant:
25        (a) statements made by the owner or person in control
26    of the substance concerning its nature, use or effect;

 

 

HB3721- 48 -LRB103 30237 AMQ 56665 b

1        (b) statements made to the buyer or recipient that the
2    substance may be resold for profit;
3        (c) whether the substance is packaged in a manner
4    normally used for the illegal distribution of controlled
5    substances;
6        (d) whether the distribution or attempted distribution
7    included an exchange of or demand for money or other
8    property as consideration, and whether the amount of the
9    consideration was substantially greater than the
10    reasonable retail market value of the substance.
11    Clause (1) of this subsection (y) shall not apply to a
12noncontrolled substance in its finished dosage form that was
13initially introduced into commerce prior to the initial
14introduction into commerce of a controlled substance in its
15finished dosage form which it may substantially resemble.
16    Nothing in this subsection (y) prohibits the dispensing or
17distributing of noncontrolled substances by persons authorized
18to dispense and distribute controlled substances under this
19Act, provided that such action would be deemed to be carried
20out in good faith under subsection (u) if the substances
21involved were controlled substances.
22    Nothing in this subsection (y) or in this Act prohibits
23the manufacture, preparation, propagation, compounding,
24processing, packaging, advertising or distribution of a drug
25or drugs by any person registered pursuant to Section 510 of
26the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360).

 

 

HB3721- 49 -LRB103 30237 AMQ 56665 b

1    (y-1) "Mail-order pharmacy" means a pharmacy that is
2located in a state of the United States that delivers,
3dispenses or distributes, through the United States Postal
4Service or other common carrier, to Illinois residents, any
5substance which requires a prescription.
6    (z) "Manufacture" means the production, preparation,
7propagation, compounding, conversion or processing of a
8controlled substance other than methamphetamine, either
9directly or indirectly, by extraction from substances of
10natural origin, or independently by means of chemical
11synthesis, or by a combination of extraction and chemical
12synthesis, and includes any packaging or repackaging of the
13substance or labeling of its container, except that this term
14does not include:
15        (1) by an ultimate user, the preparation or
16    compounding of a controlled substance for his or her own
17    use;
18        (2) by a practitioner, or his or her authorized agent
19    under his or her supervision, the preparation,
20    compounding, packaging, or labeling of a controlled
21    substance:
22            (a) as an incident to his or her administering or
23        dispensing of a controlled substance in the course of
24        his or her professional practice; or
25            (b) as an incident to lawful research, teaching or
26        chemical analysis and not for sale; or

 

 

HB3721- 50 -LRB103 30237 AMQ 56665 b

1        (3) the packaging, repackaging, or labeling of drugs
2    only to the extent permitted under the Illinois Drug Reuse
3    Opportunity Program Act.
4    (z-1) (Blank).
5    (z-5) "Medication shopping" means the conduct prohibited
6under subsection (a) of Section 314.5 of this Act.
7    (z-10) "Mid-level practitioner" means (i) a physician
8assistant who has been delegated authority to prescribe
9through a written delegation of authority by a physician
10licensed to practice medicine in all of its branches, in
11accordance with Section 7.5 of the Physician Assistant
12Practice Act of 1987, (ii) an advanced practice registered
13nurse who has been delegated authority to prescribe through a
14written delegation of authority by a physician licensed to
15practice medicine in all of its branches or by a podiatric
16physician, in accordance with Section 65-40 of the Nurse
17Practice Act, (iii) an advanced practice registered nurse
18certified as a nurse practitioner, nurse midwife, or clinical
19nurse specialist who has been granted authority to prescribe
20by a hospital affiliate in accordance with Section 65-45 of
21the Nurse Practice Act, (iv) an animal euthanasia agency, or
22(v) a prescribing psychologist.
23    (aa) "Narcotic drug" means any of the following, whether
24produced directly or indirectly by extraction from substances
25of vegetable origin, or independently by means of chemical
26synthesis, or by a combination of extraction and chemical

 

 

HB3721- 51 -LRB103 30237 AMQ 56665 b

1synthesis:
2        (1) opium, opiates, derivatives of opium and opiates,
3    including their isomers, esters, ethers, salts, and salts
4    of isomers, esters, and ethers, whenever the existence of
5    such isomers, esters, ethers, and salts is possible within
6    the specific chemical designation; however the term
7    "narcotic drug" does not include the isoquinoline
8    alkaloids of opium;
9        (2) (blank);
10        (3) opium poppy and poppy straw;
11        (4) coca leaves, except coca leaves and extracts of
12    coca leaves from which substantially all of the cocaine
13    and ecgonine, and their isomers, derivatives and salts,
14    have been removed;
15        (5) cocaine, its salts, optical and geometric isomers,
16    and salts of isomers;
17        (6) ecgonine, its derivatives, their salts, isomers,
18    and salts of isomers;
19        (7) any compound, mixture, or preparation which
20    contains any quantity of any of the substances referred to
21    in subparagraphs (1) through (6).
22    (bb) "Nurse" means a registered nurse licensed under the
23Nurse Practice Act.
24    (cc) (Blank).
25    (dd) "Opiate" means any substance having an addiction
26forming or addiction sustaining liability similar to morphine

 

 

HB3721- 52 -LRB103 30237 AMQ 56665 b

1or being capable of conversion into a drug having addiction
2forming or addiction sustaining liability.
3    (ee) "Opium poppy" means the plant of the species Papaver
4somniferum L., except its seeds.
5    (ee-5) "Oral dosage" means a tablet, capsule, elixir, or
6solution or other liquid form of medication intended for
7administration by mouth, but the term does not include a form
8of medication intended for buccal, sublingual, or transmucosal
9administration.
10    (ff) "Parole and Pardon Board" means the Parole and Pardon
11Board of the State of Illinois or its successor agency.
12    (gg) "Person" means any individual, corporation,
13mail-order pharmacy, government or governmental subdivision or
14agency, business trust, estate, trust, partnership or
15association, or any other entity.
16    (hh) "Pharmacist" means any person who holds a license or
17certificate of registration as a registered pharmacist, a
18local registered pharmacist or a registered assistant
19pharmacist under the Pharmacy Practice Act.
20    (ii) "Pharmacy" means any store, ship or other place in
21which pharmacy is authorized to be practiced under the
22Pharmacy Practice Act.
23    (ii-5) "Pharmacy shopping" means the conduct prohibited
24under subsection (b) of Section 314.5 of this Act.
25    (ii-10) "Physician" (except when the context otherwise
26requires) means a person licensed to practice medicine in all

 

 

HB3721- 53 -LRB103 30237 AMQ 56665 b

1of its branches.
2    (jj) "Poppy straw" means all parts, except the seeds, of
3the opium poppy, after mowing.
4    (kk) "Practitioner" means a physician licensed to practice
5medicine in all its branches, dentist, optometrist, podiatric
6physician, naturopathic physician, veterinarian, scientific
7investigator, pharmacist, physician assistant, advanced
8practice registered nurse, licensed practical nurse,
9registered nurse, emergency medical services personnel,
10hospital, laboratory, or pharmacy, or other person licensed,
11registered, or otherwise lawfully permitted by the United
12States or this State to distribute, dispense, conduct research
13with respect to, administer or use in teaching or chemical
14analysis, a controlled substance in the course of professional
15practice or research.
16    (ll) "Pre-printed prescription" means a written
17prescription upon which the designated drug has been indicated
18prior to the time of issuance; the term does not mean a written
19prescription that is individually generated by machine or
20computer in the prescriber's office.
21    (mm) "Prescriber" means a physician licensed to practice
22medicine in all its branches, dentist, optometrist,
23prescribing psychologist licensed under Section 4.2 of the
24Clinical Psychologist Licensing Act with prescriptive
25authority delegated under Section 4.3 of the Clinical
26Psychologist Licensing Act, podiatric physician, naturopathic

 

 

HB3721- 54 -LRB103 30237 AMQ 56665 b

1physician, or veterinarian who issues a prescription, a
2physician assistant who issues a prescription for a controlled
3substance in accordance with Section 303.05, a written
4delegation, and a written collaborative agreement required
5under Section 7.5 of the Physician Assistant Practice Act of
61987, an advanced practice registered nurse with prescriptive
7authority delegated under Section 65-40 of the Nurse Practice
8Act and in accordance with Section 303.05, a written
9delegation, and a written collaborative agreement under
10Section 65-35 of the Nurse Practice Act, an advanced practice
11registered nurse certified as a nurse practitioner, nurse
12midwife, or clinical nurse specialist who has been granted
13authority to prescribe by a hospital affiliate in accordance
14with Section 65-45 of the Nurse Practice Act and in accordance
15with Section 303.05, or an advanced practice registered nurse
16certified as a nurse practitioner, nurse midwife, or clinical
17nurse specialist who has full practice authority pursuant to
18Section 65-43 of the Nurse Practice Act.
19    (nn) "Prescription" means a written, facsimile, or oral
20order, or an electronic order that complies with applicable
21federal requirements, of a physician licensed to practice
22medicine in all its branches, dentist, podiatric physician,
23naturopathic physician, or veterinarian for any controlled
24substance, of an optometrist in accordance with Section 15.1
25of the Illinois Optometric Practice Act of 1987, of a
26prescribing psychologist licensed under Section 4.2 of the

 

 

HB3721- 55 -LRB103 30237 AMQ 56665 b

1Clinical Psychologist Licensing Act with prescriptive
2authority delegated under Section 4.3 of the Clinical
3Psychologist Licensing Act, of a physician assistant for a
4controlled substance in accordance with Section 303.05, a
5written delegation, and a written collaborative agreement
6required under Section 7.5 of the Physician Assistant Practice
7Act of 1987, of an advanced practice registered nurse with
8prescriptive authority delegated under Section 65-40 of the
9Nurse Practice Act who issues a prescription for a controlled
10substance in accordance with Section 303.05, a written
11delegation, and a written collaborative agreement under
12Section 65-35 of the Nurse Practice Act, of an advanced
13practice registered nurse certified as a nurse practitioner,
14nurse midwife, or clinical nurse specialist who has been
15granted authority to prescribe by a hospital affiliate in
16accordance with Section 65-45 of the Nurse Practice Act and in
17accordance with Section 303.05 when required by law, or of an
18advanced practice registered nurse certified as a nurse
19practitioner, nurse midwife, or clinical nurse specialist who
20has full practice authority pursuant to Section 65-43 of the
21Nurse Practice Act.
22    (nn-5) "Prescription Information Library" (PIL) means an
23electronic library that contains reported controlled substance
24data.
25    (nn-10) "Prescription Monitoring Program" (PMP) means the
26entity that collects, tracks, and stores reported data on

 

 

HB3721- 56 -LRB103 30237 AMQ 56665 b

1controlled substances and select drugs pursuant to Section
2316.
3    (oo) "Production" or "produce" means manufacture,
4planting, cultivating, growing, or harvesting of a controlled
5substance other than methamphetamine.
6    (pp) "Registrant" means every person who is required to
7register under Section 302 of this Act.
8    (qq) "Registry number" means the number assigned to each
9person authorized to handle controlled substances under the
10laws of the United States and of this State.
11    (qq-5) "Secretary" means, as the context requires, either
12the Secretary of the Department or the Secretary of the
13Department of Financial and Professional Regulation, and the
14Secretary's designated agents.
15    (rr) "State" includes the State of Illinois and any state,
16district, commonwealth, territory, insular possession thereof,
17and any area subject to the legal authority of the United
18States of America.
19    (rr-5) "Stimulant" means any drug that (i) causes an
20overall excitation of central nervous system functions, (ii)
21causes impaired consciousness and awareness, and (iii) can be
22habit-forming or lead to a substance abuse problem, including,
23but not limited to, amphetamines and their analogs,
24methylphenidate and its analogs, cocaine, and phencyclidine
25and its analogs.
26    (rr-10) "Synthetic drug" includes, but is not limited to,

 

 

HB3721- 57 -LRB103 30237 AMQ 56665 b

1any synthetic cannabinoids or piperazines or any synthetic
2cathinones as provided for in Schedule I.
3    (ss) "Ultimate user" means a person who lawfully possesses
4a controlled substance for his or her own use or for the use of
5a member of his or her household or for administering to an
6animal owned by him or her or by a member of his or her
7household.
8(Source: P.A. 101-666, eff. 1-1-22; 102-389, eff. 1-1-22;
9102-538, eff. 8-20-21; 102-813, eff. 5-13-22.)
 
10    Section 999. Effective date. This Act takes effect upon
11becoming law.